Bullish
$CYCC catalysts 1 - Report updated Phase 1 safety, pharmacokinetics and efficacy data for CYC065 utilizing a frequent dosing schedule in patients with advanced solid cancers; 2 - Report initial safety and PK data from the Phase 1 study of an oral formulation of CYC065; 3 - Report initial safety and proof of concept data from the CYC065-venetoclax Phase 1 study in relapsed/refractory AML and MDS; 4 - Report initial safety and proof of concept data from the CYC065-venetoclax Phase 1 study in relapsed/refractory CLL; 5 - Report initial data from the sapacitabine-venetoclax Phase 1/2 study in patients with relapsed or refractory AML or MDS; 6 - Report initial data from the CYC140 Phase 1 First-in-Human study in relapsed or refractory leukemias; and 7 - Report data from the Phase 1b/2 IST of sapacitabine-olaparib combination in patients with BRCA mutant metastatic breast cancer when reported by the investigators.
  • 2
  • 1